- Home
- CRSP vs SFBS Comparison
CRSP vs SFBS Comparison
Compare CRSP & SFBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- SFBS
- Stock Information
- Founded
- CRSP 2013
- SFBS 2005
- Country
- CRSP Switzerland
- SFBS United States
- Employees
- CRSP N/A
- SFBS N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- SFBS Major Banks
- Sector
- CRSP Health Care
- SFBS Finance
- Exchange
- CRSP Nasdaq
- SFBS Nasdaq
- Market Cap
- CRSP 4.9B
- SFBS 4.9B
- IPO Year
- CRSP 2016
- SFBS 2014
- Fundamental
- Price
- CRSP $51.83
- SFBS $88.19
- Analyst Decision
- CRSP Buy
- SFBS Hold
- Analyst Count
- CRSP 16
- SFBS 1
- Target Price
- CRSP $72.27
- SFBS $90.00
- AVG Volume (30 Days)
- CRSP 2.5M
- SFBS 203.4K
- Earning Date
- CRSP 08-04-2025
- SFBS 10-20-2025
- Dividend Yield
- CRSP N/A
- SFBS 1.52%
- EPS Growth
- CRSP N/A
- SFBS 26.23
- EPS
- CRSP N/A
- SFBS 4.57
- Revenue
- CRSP $38,050,000.00
- SFBS $488,391,000.00
- Revenue This Year
- CRSP $11.17
- SFBS $25.86
- Revenue Next Year
- CRSP $296.09
- SFBS $14.42
- P/E Ratio
- CRSP N/A
- SFBS $19.29
- Revenue Growth
- CRSP N/A
- SFBS 18.16
- 52 Week Low
- CRSP $30.04
- SFBS $66.48
- 52 Week High
- CRSP $71.13
- SFBS $101.37
- Technical
- Relative Strength Index (RSI)
- CRSP 40.26
- SFBS 67.57
- Support Level
- CRSP $51.80
- SFBS $87.93
- Resistance Level
- CRSP $55.30
- SFBS $90.64
- Average True Range (ATR)
- CRSP 2.23
- SFBS 1.91
- MACD
- CRSP -0.58
- SFBS 0.68
- Stochastic Oscillator
- CRSP 4.66
- SFBS 79.65
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About SFBS ServisFirst Bancshares Inc.
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary, ServisFirst Bank. Through the bank, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.